- Home
- QQQX vs PCRX Comparison
QQQX vs PCRX Comparison
Compare QQQX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- PCRX
- Stock Information
- Founded
- QQQX 2007
- PCRX 2006
- Country
- QQQX United States
- PCRX United States
- Employees
- QQQX N/A
- PCRX N/A
- Industry
- QQQX Finance Companies
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- PCRX Health Care
- Exchange
- QQQX Nasdaq
- PCRX Nasdaq
- Market Cap
- QQQX 1.2B
- PCRX 1.2B
- IPO Year
- QQQX N/A
- PCRX 2011
- Fundamental
- Price
- QQQX $26.48
- PCRX $23.22
- Analyst Decision
- QQQX
- PCRX Buy
- Analyst Count
- QQQX 0
- PCRX 8
- Target Price
- QQQX N/A
- PCRX $28.38
- AVG Volume (30 Days)
- QQQX 127.6K
- PCRX 569.8K
- Earning Date
- QQQX 01-01-0001
- PCRX 07-29-2025
- Dividend Yield
- QQQX 7.03%
- PCRX N/A
- EPS Growth
- QQQX N/A
- PCRX N/A
- EPS
- QQQX N/A
- PCRX N/A
- Revenue
- QQQX N/A
- PCRX $702,772,000.00
- Revenue This Year
- QQQX N/A
- PCRX $7.54
- Revenue Next Year
- QQQX N/A
- PCRX $10.78
- P/E Ratio
- QQQX N/A
- PCRX N/A
- Revenue Growth
- QQQX N/A
- PCRX 3.08
- 52 Week Low
- QQQX $20.27
- PCRX $11.16
- 52 Week High
- QQQX $25.99
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- QQQX 66.23
- PCRX 35.42
- Support Level
- QQQX $26.27
- PCRX $22.82
- Resistance Level
- QQQX $26.60
- PCRX $24.36
- Average True Range (ATR)
- QQQX 0.30
- PCRX 0.69
- MACD
- QQQX 0.04
- PCRX -0.12
- Stochastic Oscillator
- QQQX 91.72
- PCRX 17.09
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.